Valens: Canaccord Lowers Price Target To $3.75

Earlier this month, The Valens Company (TSX: VLNS) reported their fiscal third-quarter financial results. The company reported net revenue of $20.99 million, up from the $18.76 million reported last quarter. Gross margins were 26.8% for the quarter compared to 22% last quarter, while adjusted EBITDA came in lower than last quarter at negative $6.18 million. The company reported a net loss of $12.8 million. Valens saw its SKU count go from 75 at the end of the first fiscal quarter to now 181 at the end of this quarter.

The Valens Company currently has 9 analysts covering the stock with an average 12-month price target of C$3.92, or 89% upside. Out of the 9 analysts, 1 has a strong buy rating, 7 have buys and 1 analyst has a hold rating. The street high sits at C$5.25 from Stifel-GMP, while the lowest comes in at C$2.50.

In a note, Canaccord Genuity lowered their price target to C$3.75 from $4.25 and speculative buy rating saying that after their first run-through the company is now focusing on margins. For the quarter, Canaccord forecasted revenue to be C$22.5 million.

Canaccord notes that this quarter included partial sales from Green Roads which accounted for C$4.7 million, so if you would back that out then sales would have declined by 12%. They write that this decline would be attributed to the company “transitioning away from smaller, underperforming B2B partners in favour of building deeper relationships with larger LPs.”

Onto gross margins, the company saw a 4.8% increase in gross margins, which can be partially attributed to the Green Roads inclusion. Canaccord writes, “Having now achieved critical mass for its SKU listings, VLNS plans to shift focus to driving margin expansion through automation, volume growth, and operational efficiencies.”


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Why the Market May Be Misreading Iran | David Woo

Why US Fertilizer Supply Could Matter a Lot More Now | Pat Varas – Sage Potash

Roscan Gold: Mali Discount Hits Kandiole PEA

Recommended

Antimony Resources Expands New Discovery Following Trenching

Silver47 Kicks Off 7,000-Meter Drill Campaign at Nevada’s Hughes Project

Related News

Equinox Gold: The Analyst First Impression Of The Premier Gold Mines Transaction

Earlier this week, Equinox Gold Corp (TSX: EQX) announced the acquisition of Premier Gold Mines...

Saturday, December 19, 2020, 01:39:00 PM

Cannabis Earnings: Cantor Fitzgerald Adjusts Ratings Ahead Of Earnings

Last week, Pablo Zuanic from Cantor Fitzgerald released his second-quarter estimates and updated his 12-month...

Wednesday, August 11, 2021, 09:56:00 AM

Organigram Sees Canaccord Raise Price Target To $3.25 After Earnings

On January 11th, Organigram Holdings (TSX: OGI) issued its second fiscal quarter of 2022. The...

Thursday, January 13, 2022, 03:48:00 PM

Canadian Cannabis: Canaccord Lifts Cronos Target, Reiterates Canopy Growth And Tilray Ratings

Yesterday Canaccord Genuity Capital Markets put out a second-quarter preview note on the top Canadian...

Thursday, July 28, 2022, 03:02:00 PM

Medmen: Cantor Reiterates Ratings After Call With Management

On September 23, Medmen Enterprises (CSE: MMEN) reported their fiscal fourth quarter financial results. The...

Friday, October 8, 2021, 03:42:00 PM